Quick Answer
GUIDED THERAPEUTICS INC reported Research And Development Expense of $469.0 thousand for the year ending 2025.
- GUIDED THERAPEUTICS INC showed a decrease of -10.8% in Research And Development Expense from 2024 to 2025.
- This data is from GUIDED THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2015: $305.0 thousand | Q3 2015: $413.0 thousand | Q1 2016: $290.0 thousand | Q2 2016: $148.0 thousand | Q3 2016: $87.0 thousand | Q1 2017: $91.0 thousand | Q2 2017: $89.0 thousand | Q3 2017: $69.0 thousand | Q1 2018: $69.0 thousand | Q2 2018: $62.0 thousand | Q3 2018: $43.0 thousand | Q1 2019: $47.0 thousand | Q2 2019: $43.0 thousand | Q3 2019: $23.0 thousand | Q1 2020: $24.0 thousand | Q2 2020: $55.0 thousand | Q3 2020: $41.0 thousand | Q1 2021: $16.0 thousand | Q2 2021: $20.0 thousand | Q3 2021: $16.0 thousand | Q1 2022: $21.0 thousand | Q2 2022: $9.0 thousand | Q3 2022: $8.0 thousand | Q1 2023: $7.0 thousand | Q2 2023: $66.0 thousand | Q3 2023: $69.0 thousand | Q1 2024: $54.0 thousand | Q2 2024: $222.0 thousand | Q3 2024: $111.0 thousand | Q1 2025: $74.0 thousand | Q2 2025: $133.0 thousand | Q3 2025: $136.0 thousand.
- Over the full 16 years of available data (2010 to 2025), GUIDED THERAPEUTICS INC's Research And Development Expense has declined by 74.0%.
- Historical annual values: Fiscal year 2025: $469.0 thousand | Fiscal year 2024: $526.0 thousand | Fiscal year 2023: $228.0 thousand | Fiscal year 2022: $77.0 thousand | Fiscal year 2021: $69.0 thousand | Fiscal year 2020: $143.0 thousand | Fiscal year 2019: $122.0 thousand | Fiscal year 2018: $244.0 thousand | Fiscal year 2017: $334.0 thousand | Fiscal year 2016: $733.0 thousand | Fiscal year 2015: $1.48 million | Fiscal year 2014: $2.79 million | Fiscal year 2013: $2.74 million | Fiscal year 2012: $3.23 million | Fiscal year 2011: $2.78 million | Fiscal year 2010: $1.81 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: